The Second Hospital of Shandong University | China
Author Profile
Scopus
Early Academic Pursuits
Dr. Feifei Feng embarked on her academic journey in clinical medicine, obtaining a Master's degree through a seven-year program at Zhejiang University (2005-2012). She continued her education with a Doctor of Medicine (MD) degree in Internal Medicine from Qilu Medical College, Shandong University (2017-2020). Her academic training laid a robust foundation in both clinical and research aspects of internal medicine, particularly focusing on respiratory and critical care.
Professional Endeavors
Dr. Feng's professional career has been marked by her role as an Associate Chief Physician in the Department of Respiratory and Critical Care Medicine at the Second Hospital of Shandong University (09/2022 - Present). In this capacity, she is responsible for the daily consultation and treatment of patients with respiratory and critical care needs. Her work emphasizes the diagnosis and management of respiratory diseases, with a particular focus on lung cancer and pulmonary fibrosis.
Contributions and Research Focus
Dr. Feng's research has significantly contributed to understanding and treating respiratory diseases. Her research focus includes:
*Silicosis and Pulmonary Fibrosis: Dr. Feng has extensively studied the pathogenesis of silicosis and the therapeutic effects of compounds like Tanshinone IIA in attenuating silica-induced pulmonary fibrosis.
*Cancer Therapy: Her work on the inhibitory effects of polyphyllins and their role in enhancing chemosensitivity of cancer cells to treatments like cisplatin has been groundbreaking.
*Signaling Pathways: She has delved into the molecular mechanisms underlying disease processes, such as the TGF-β1/Smad signaling pathway, EMT, NOX4 inhibition, and Nrf2/ARE signaling activation.
Accolades and Recognition
Dr. Feng's contributions to the field have been widely recognized through numerous publications in high-impact journals. Some of her notable works include:
"Role of TRIM59 in regulating PPM1A in the pathogenesis of silicosis and the intervention effect of tanshinone IIA" (Biomed Pharmacother, 2024).
"Tanshinone IIA attenuates silica-induced pulmonary fibrosis via Nrf2-mediated inhibition of EMT and TGF-β1/Smad signaling" (Chem Biol Interact, 2020).
Impact and Influence
Dr. Feng's research has had a profound impact on the medical community's understanding of respiratory diseases and their treatment. Her studies on the molecular pathways involved in pulmonary fibrosis and cancer therapy have opened new avenues for developing targeted treatments. By elucidating the mechanisms of disease and identifying potential therapeutic agents, her work has contributed to improved patient outcomes and advanced the field of respiratory medicine.
Legacy and Future Contributions
Dr. Feng continues to make strides in her field through her ongoing clinical practice and research. Her dedication to understanding complex respiratory diseases and finding innovative treatments ensures that her contributions will have a lasting impact. Future research endeavors are likely to build on her current work, exploring new therapeutic targets and improving the quality of care for patients with respiratory diseases. Her legacy will be marked by her commitment to advancing medical science and improving patient health outcomes.
Notable Publications
Role of TRIM59 in regulating PPM1A in the pathogenesis of silicosis and the intervention effect of tanshinone IIA 2024
Inhibitory effects of polyphyllins I and VII on human cisplatin-resistant NSCLC via p53 upregulation and CIP2A/AKT/mTOR signaling axis inhibition 2019 (26)
Tanshinone IIA attenuates silica-induced pulmonary fibrosis via Nrf2-mediated inhibition of EMT and TGF-β1/Smad signaling 2020 (52)
Astragaloside IV alleviates silica‑induced pulmonary fibrosis via inactivation of the TGF‑β1/Smad2/3 signaling pathway 2021 (23)